Knight Therapeutics Past Earnings Performance
Past criteria checks 0/6
Knight Therapeutics's earnings have been declining at an average annual rate of -45.5%, while the Pharmaceuticals industry saw earnings growing at 31.5% annually. Revenues have been growing at an average rate of 37.9% per year.
Key information
-45.5%
Earnings growth rate
-45.5%
EPS growth rate
Pharmaceuticals Industry Growth | 23.1% |
Revenue growth rate | 37.9% |
Return on equity | -2.3% |
Net Margin | -5.1% |
Next Earnings Update | 09 May 2024 |
Recent past performance updates
Recent updates
Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?
May 28Shareholders May Not Be So Generous With Knight Therapeutics Inc.'s (TSE:GUD) CEO Compensation And Here's Why
May 07Calculating The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)
Apr 07Read This Before Selling Knight Therapeutics Inc. (TSE:GUD) Shares
Mar 20If You Had Bought Knight Therapeutics' (TSE:GUD) Shares Three Years Ago You Would Be Down 34%
Mar 02Knight Therapeutics (TSE:GUD) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Feb 03Knight Therapeutics's (TSE:GUD) Earnings Are Growing But Is There More To The Story?
Jan 19What Type Of Shareholders Own The Most Number of Knight Therapeutics Inc. (TSE:GUD) Shares?
Jan 04A Look At The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)
Dec 20The Founder of Knight Therapeutics Inc. (TSE:GUD), Jonathan Goodman, Just Bought A Few More Shares
Dec 07What Type Of Returns Would Knight Therapeutics'(TSE:GUD) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Dec 02Need To Know: The Consensus Just Cut Its Knight Therapeutics Inc. (TSE:GUD) Estimates For 2021
Nov 17Revenue & Expenses BreakdownBeta
How Knight Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 328 | -17 | 84 | 18 |
30 Sep 23 | 336 | -8 | 90 | 17 |
30 Jun 23 | 326 | -16 | 90 | 17 |
31 Mar 23 | 312 | -15 | 90 | 16 |
31 Dec 22 | 294 | -30 | 89 | 15 |
30 Sep 22 | 270 | -23 | 86 | 14 |
30 Jun 22 | 271 | -33 | 81 | 14 |
31 Mar 22 | 261 | -7 | 78 | 13 |
31 Dec 21 | 243 | 16 | 74 | 13 |
30 Sep 21 | 240 | 32 | 68 | 13 |
30 Jun 21 | 212 | 59 | 69 | 12 |
31 Mar 21 | 200 | 47 | 67 | 12 |
31 Dec 20 | 200 | 42 | 71 | 12 |
30 Sep 20 | 182 | 27 | 65 | 9 |
30 Jun 20 | 140 | 6 | 53 | 7 |
31 Mar 20 | 90 | 8 | 38 | 6 |
31 Dec 19 | 47 | 15 | 24 | 4 |
30 Sep 19 | 14 | 21 | 17 | 3 |
30 Jun 19 | 13 | 37 | 13 | 3 |
31 Mar 19 | 12 | 22 | 14 | 2 |
31 Dec 18 | 13 | 24 | 12 | 2 |
30 Sep 18 | 11 | 31 | 11 | 2 |
30 Jun 18 | 10 | 22 | 11 | 3 |
31 Mar 18 | 10 | 18 | 12 | 3 |
31 Dec 17 | 9 | 17 | 12 | 3 |
30 Sep 17 | 8 | 18 | 12 | 3 |
30 Jun 17 | 8 | 20 | 12 | 2 |
31 Mar 17 | 7 | 24 | 10 | 2 |
31 Dec 16 | 6 | 19 | 10 | 2 |
30 Sep 16 | 4 | 16 | 9 | 1 |
30 Jun 16 | 3 | 17 | 8 | 3 |
31 Mar 16 | 2 | 21 | 9 | 3 |
31 Dec 15 | 1 | 34 | 9 | 3 |
30 Sep 15 | 1 | 154 | 10 | 3 |
30 Jun 15 | 1 | 148 | 9 | 2 |
31 Mar 15 | 1 | 140 | 7 | 1 |
31 Dec 14 | 0 | 126 | 4 | 1 |
Quality Earnings: GUD is currently unprofitable.
Growing Profit Margin: GUD is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GUD is unprofitable, and losses have increased over the past 5 years at a rate of 45.5% per year.
Accelerating Growth: Unable to compare GUD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GUD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22%).
Return on Equity
High ROE: GUD has a negative Return on Equity (-2.25%), as it is currently unprofitable.